» Articles » PMID: 23236499

Brain Gene Expression of a Sporadic (icv-STZ Mouse) and a Familial Mouse Model (3xTg-AD Mouse) of Alzheimer's Disease

Overview
Journal PLoS One
Date 2012 Dec 14
PMID 23236499
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) can be divided into sporadic AD (SAD) and familial AD (FAD). Most AD cases are sporadic and may result from multiple etiologic factors, including environmental, genetic and metabolic factors, whereas FAD is caused by mutations of presenilins or amyloid-β (Aβ) precursor protein (APP). A commonly used mouse model for AD is 3xTg-AD mouse, which is generated by over-expression of mutated presenilin 1, APP and tau in the brain and thus represents a mouse model of FAD. A mouse model generated by intracerebroventricular (icv) administration of streptozocin (STZ), icv-STZ mouse, shows many aspects of SAD. Despite the wide use of these two models for AD research, differences in gene expression between them are not known. Here, we compared the expression of 84 AD-related genes in the hippocampus and the cerebral cortex between icv-STZ mice and 3xTg-AD mice using a custom-designed qPCR array. These genes are involved in APP processing, tau/cytoskeleton, synapse function, apoptosis and autophagy, AD-related protein kinases, glucose metabolism, insulin signaling, and mTOR pathway. We found altered expression of around 20 genes in both mouse models, which affected each of above categories. Many of these gene alterations were consistent with what was observed in AD brain previously. The expression of most of these altered genes was decreased or tended to be decreased in the hippocampus of both mouse models. Significant diversity in gene expression was found in the cerebral cortex between these two AD mouse models. More genes related to synaptic function were dysregulated in the 3xTg-AD mice, whereas more genes related to insulin signaling and glucose metabolism were down-regulated in the icv-STZ mice. The present study provides important fundamental knowledge of these two AD mouse models and will help guide future studies using these two mouse models for the development of AD drugs.

Citing Articles

Canagliflozin Mitigated Cognitive Impairment in Streptozotocin-Induced Sporadic Alzheimer's Disease in Mice: Role of AMPK/SIRT-1 Signaling Pathway in Modulating Neuroinflammation.

Khamies S, El-Yamany M, Ibrahim S J Neuroimmune Pharmacol. 2024; 19(1):39.

PMID: 39073453 DOI: 10.1007/s11481-024-10140-y.


Astrocyte metabolism and signaling pathways in the CNS.

Zhang Y, Qi Y, Gao Y, Chen W, Zhou T, Zang Y Front Neurosci. 2023; 17:1217451.

PMID: 37732313 PMC: 10507181. DOI: 10.3389/fnins.2023.1217451.


State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer's Disease.

Rhea E, Leclerc M, Yassine H, Capuano A, Tong H, Petyuk V Aging Dis. 2023; 15(4):1688-1725.

PMID: 37611907 PMC: 11272209. DOI: 10.14336/AD.2023.0814.


From attention-deficit hyperactivity disorder to sporadic Alzheimer's disease-Wnt/mTOR pathways hypothesis.

Grunblatt E, Homolak J, Babic Perhoc A, Davor V, Knezovic A, Osmanovic Barilar J Front Neurosci. 2023; 17:1104985.

PMID: 36875654 PMC: 9978448. DOI: 10.3389/fnins.2023.1104985.


The Ameliorative Impact of on the Working Memory Deficit in Streptozotocin-induced Rat Model of Alzheimer Disease.

Sahraei R, Aminyavari S, Hosseini M, Hassanzadeh-Taheri M, Foadoddini M, Saebipour M Basic Clin Neurosci. 2023; 13(1):25-34.

PMID: 36589020 PMC: 9790102. DOI: 10.32598/bcn.2021.144.4.


References
1.
Iqbal K, Grundke-Iqbal I . Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. Acta Neuropathol. 2005; 109(1):25-31. DOI: 10.1007/s00401-004-0951-y. View

2.
Shen J, Kelleher 3rd R . The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A. 2007; 104(2):403-9. PMC: 1766397. DOI: 10.1073/pnas.0608332104. View

3.
Steen E, Terry B, Rivera E, Cannon J, Neely T, Tavares R . Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?. J Alzheimers Dis. 2005; 7(1):63-80. DOI: 10.3233/jad-2005-7107. View

4.
Brooks W, Lynch P, Ingle C, Hatton A, Emson P, Faull R . Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease. Brain Res. 2006; 1127(1):127-35. DOI: 10.1016/j.brainres.2006.09.106. View

5.
Muller M, Cardenas C, Mei L, Cheung K, Foskett J . Constitutive cAMP response element binding protein (CREB) activation by Alzheimer's disease presenilin-driven inositol trisphosphate receptor (InsP3R) Ca2+ signaling. Proc Natl Acad Sci U S A. 2011; 108(32):13293-8. PMC: 3156223. DOI: 10.1073/pnas.1109297108. View